ATE368034T1 - Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase - Google Patents

Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase

Info

Publication number: ATE368034T1
Authority: AT; Austria
Prior art keywords: kinase; inhibitors; heteroaryl; substituted biphenyl; biphenyl derivatives
Prior art date: 2002-04-30

Application number

AT03747504T

Other languages

English (en)

Inventor

Richard M Angell

Paul Bamborough

Ian R Baldwin

Anne-Marie Li-Kwai-Cheung

Timothy Longstaff

Suzanne Joy Merrick

Kathryn Jane Smith

Stephen Swanson

Ann Louise Walker

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-04-30

Filing date

2003-04-29

Publication date

2007-08-15

2003-04-29 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

2007-08-15 Application granted granted Critical

2007-08-15 Publication of ATE368034T1 publication Critical patent/ATE368034T1/de

Links

239000003112 inhibitor Substances 0.000 title abstract 2
108091000080 Phosphotransferase Proteins 0.000 title 1
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 title 1
102000020233 phosphotransferase Human genes 0.000 title 1
102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 abstract 3
230000000694 effects Effects 0.000 abstract 2
230000001404 mediated effect Effects 0.000 abstract 2
102000004127 Cytokines Human genes 0.000 abstract 1
108090000695 Cytokines Proteins 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Hematology (AREA)
Tropical Medicine & Parasitology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Dermatology (AREA)
Virology (AREA)
Ophthalmology & Optometry (AREA)
Molecular Biology (AREA)
Obesity (AREA)

AT03747504T 2002-04-30 2003-04-29 Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase ATE368034T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0209891.1A GB0209891D0 (en)	2002-04-30	2002-04-30	Novel compounds

Publications (1)

Publication Number	Publication Date
ATE368034T1 true ATE368034T1 (de)	2007-08-15

Family

ID=9935812

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03747504T ATE368034T1 (de)	2002-04-30	2003-04-29	Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase

Country Status (9)

Country	Link
US (1)	US7425555B2 (de)
EP (1)	EP1499600B1 (de)
JP (1)	JP2005535586A (de)
AT (1)	ATE368034T1 (de)
AU (1)	AU2003226572A1 (de)
DE (1)	DE60315146T2 (de)
ES (1)	ES2290486T3 (de)
GB (1)	GB0209891D0 (de)
WO (1)	WO2003093248A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20020506A1 (es)	2000-08-22	2002-07-09	Glaxo Group Ltd	Derivados de pirazol fusionados como inhibidores de la proteina cinasa
GB0124931D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124938D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124939D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124936D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124934D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124941D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124933D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
BRPI0307351B8 (pt)	2002-02-12	2021-05-25	Smithkline Beecham Corp	composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
GB0209891D0 (en)	2002-04-30	2002-06-05	Glaxo Group Ltd	Novel compounds
GB0217757D0 (en)	2002-07-31	2002-09-11	Glaxo Group Ltd	Novel compounds
GB0308186D0 (en)	2003-04-09	2003-05-14	Smithkline Beecham Corp	Novel compounds
GB0308185D0 (en)	2003-04-09	2003-05-14	Smithkline Beecham Corp	Novel compounds
GB0308201D0 (en)	2003-04-09	2003-05-14	Smithkline Beecham Corp	Novel compounds
DE602004017494D1 (de) *	2003-07-25	2008-12-11	Novartis Ag	Inhibitoren von p-38-kinase
GB0318814D0 (en) *	2003-08-11	2003-09-10	Smithkline Beecham Corp	Novel compounds
GB0402138D0 (en) *	2004-01-30	2004-03-03	Smithkline Beecham Corp	Novel compounds
GB0402140D0 (en) *	2004-01-30	2004-03-03	Smithkline Beecham Corp	Novel compounds
GB0402137D0 (en) *	2004-01-30	2004-03-03	Smithkline Beecham Corp	Novel compounds
GB0402143D0 (en) *	2004-01-30	2004-03-03	Smithkline Beecham Corp	Novel compounds
US7683097B2 (en) *	2004-05-27	2010-03-23	Propharmacon Inc.	Topoisomerase inhibitors
US20080051416A1 (en) *	2004-10-05	2008-02-28	Smithkline Beecham Corporation	Novel Compounds
JP2008516989A (ja) *	2004-10-19	2008-05-22	コンパスファーマシューティカルズリミティドライアビリティカンパニー	組成物及び抗腫瘍剤としてのその使用
BRPI0519424B8 (pt)	2004-12-28	2021-05-25	Athenex Inc	compostos, composição e uso dos ditos compostos para a preparação de um medicamento para prevenção ou tratamento de um distúrbio de proliferação celular ou infecção microbiana
US7968574B2 (en)	2004-12-28	2011-06-28	Kinex Pharmaceuticals, Llc	Biaryl compositions and methods for modulating a kinase cascade
GB0512429D0 (en) *	2005-06-17	2005-07-27	Smithkline Beecham Corp	Novel compound
AU2006290442B2 (en) *	2005-09-16	2010-07-29	Arrow Therapeutics Limited	Biphenyl derivatives and their use in treating hepatitis C
GB0612026D0 (en)	2006-06-16	2006-07-26	Smithkline Beecham Corp	New use
CN101595084B (zh)	2006-06-29	2013-01-02	金克斯医药品有限公司	用于调整激酶级联的二芳基组合物和方法
JP5638804B2 (ja)	2006-08-04	2014-12-10	アストラゼネカアクチボラグ	ＥｒｂＢ２に対する抗体
US7935697B2 (en)	2006-12-28	2011-05-03	Kinex Pharmaceuticals, Llc	Compositions for modulating a kinase cascade and methods of use thereof
US7939529B2 (en)	2007-05-17	2011-05-10	Kinex Pharmaceuticals, Llc	Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
WO2009009041A2 (en) *	2007-07-06	2009-01-15	Kinex Pharmaceuticals, Llc	Compositions and methods for modulating a kinase cascade
EP3777832A1 (de) *	2007-10-20	2021-02-17	Athenex, Inc.	Pharmazeutische zubereitung zur veränderung der kinase kasakade und deren verwendung
TWI490214B (zh)	2008-05-30	2015-07-01	艾德克上野股份有限公司	苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
CA2728769A1 (en) *	2008-07-04	2010-01-07	Bruno Villoutreix	Nitrogen heterocycle derivatives as proteasome modulators
ES2645367T3 (es)	2010-04-16	2017-12-05	Athenex, Inc.	Composiciones y métodos para la prevención y el tratamiento del cáncer
US9302996B2 (en)	2010-12-17	2016-04-05	Mitsubishi Tanabe Pharma Corporation	Continuous arycyclic compound
US9546155B2 (en)	2012-06-15	2017-01-17	Mitsubishi Tanabe Pharma Corporation	Aromatic heterocyclic compound
JP6499076B2 (ja)	2012-08-30	2019-04-10	アセネックスインコーポレイテッド	タンパク質チロシンキナーゼ調節因子としてのｎ−（３−フルオロベンジル）−２−（５−（４−モルホリノフェニル）ピリジン−２−イル）アセトアミド
TWI644899B (zh)	2013-02-04	2018-12-21	健生藥品公司	Ｆｌａｐ調節劑
WO2014121055A2 (en) *	2013-02-04	2014-08-07	Janssen Pharmaceutica Nv	Flap modulators
US20190060286A1 (en)	2016-02-29	2019-02-28	University Of Florida Research Foundation, Incorpo	Chemotherapeutic Methods
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071144A1 (en)	2017-10-05	2019-04-11	Fulcrum Therapeutics, Inc.	USE OF P38 INHIBITORS TO REDUCE DUX4 EXPRESSION
JP2021519334A (ja)	2018-03-26	2021-08-10	クリアクリークバイオ，インコーポレイテッド	ジヒドロオロト酸デヒドロゲナーゼを阻害するための組成物および方法
US20210300873A1 (en)	2020-03-20	2021-09-30	Clear Creek Bio, Inc.	Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
KR102893769B1 (ko) *	2023-04-20	2025-12-02	명지대학교 산학협력단	피롤 결찰의 옥사디아졸 유도체, 이의 제조방법 및 박테리아 감염 예방 또는 치료용 약학적 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW240217B (de) *	1992-12-30	1995-02-11	Glaxo Group Ltd
EP0733048A1 (de) *	1993-12-07	1996-09-25	Smithkline Beecham Plc	Heterocyclische biphenylylamide, verwendbar als 5ht1d antagonisten
ATE224878T1 (de) *	1996-11-04	2002-10-15	Aventis Cropscience Sa	1-polyarylpyrazole als pestizide
PE20020506A1 (es) *	2000-08-22	2002-07-09	Glaxo Group Ltd	Derivados de pirazol fusionados como inhibidores de la proteina cinasa
GB0119863D0 (en) *	2001-08-14	2001-10-10	Cancer Res Campaign Tech	DNA-PK inhibitors
GB0124928D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124932D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124934D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124939D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124936D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124938D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124933D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124941D0 (en) *	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124931D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
BRPI0307351B8 (pt)	2002-02-12	2021-05-25	Smithkline Beecham Corp	composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
GB0209891D0 (en)	2002-04-30	2002-06-05	Glaxo Group Ltd	Novel compounds
GB0217757D0 (en)	2002-07-31	2002-09-11	Glaxo Group Ltd	Novel compounds

2002
- 2002-04-30 GB GBGB0209891.1A patent/GB0209891D0/en not_active Ceased
2003
- 2003-04-29 WO PCT/GB2003/001834 patent/WO2003093248A1/en not_active Ceased
- 2003-04-29 DE DE60315146T patent/DE60315146T2/de not_active Expired - Lifetime
- 2003-04-29 AU AU2003226572A patent/AU2003226572A1/en not_active Abandoned
- 2003-04-29 AT AT03747504T patent/ATE368034T1/de not_active IP Right Cessation
- 2003-04-29 US US10/513,095 patent/US7425555B2/en not_active Expired - Fee Related
- 2003-04-29 JP JP2004501387A patent/JP2005535586A/ja active Pending
- 2003-04-29 ES ES03747504T patent/ES2290486T3/es not_active Expired - Lifetime
- 2003-04-29 EP EP03747504A patent/EP1499600B1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US7425555B2 (en)	2008-09-16
DE60315146T2 (de)	2008-04-17
US20060089393A1 (en)	2006-04-27
WO2003093248A1 (en)	2003-11-13
ES2290486T3 (es)	2008-02-16
JP2005535586A (ja)	2005-11-24
AU2003226572A1 (en)	2003-11-17
EP1499600B1 (de)	2007-07-25
DE60315146D1 (de)	2007-09-06
GB0209891D0 (en)	2002-06-05
EP1499600A1 (de)	2005-01-26

Legal Events

Date	Code	Title	Description
2008-01-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60315146D1 (de)	2007-09-06	Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
ATE517896T1 (de)	2011-08-15	P38-kinase-inhibitoren
DK1864975T3 (da)	2011-01-24	Nikotinamid-derivater anvendelige som P38-inhibitorer
GB0402143D0 (en)	2004-03-03	Novel compounds
DE60314639D1 (de)	2007-08-09	Fusionierte heteroaryl-derivative zur verwendung als p38 kinase inhibitoren zur behandlung von u.a rheumatischer arthritis
EA200600689A1 (ru)	2006-08-25	Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
EA200401284A1 (ru)	2005-04-28	Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
ATE439837T1 (de)	2009-09-15	5-gliedrige heterocyclische p-38 inhibitoren
ATE532781T1 (de)	2011-11-15	5-(acylamino)indazol-derivate als kinase- inhibitoren
DE60327999D1 (de)	2009-07-30	Azolylaminoazine als inhibitoren von proteinkinasen
BR0313330A (pt)	2005-06-14	Piperidina-ftalazonas substituìdas com pirrolidinadiona como inibidores de pde4
ATE348616T1 (de)	2007-01-15	2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
ATE353217T1 (de)	2007-02-15	3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
ATE413392T1 (de)	2008-11-15	Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren
ATE362929T1 (de)	2007-06-15	Pyridinderivate als inhibitoren der raf-kinase
DE602004005016D1 (de)	2007-04-12	Biphenylcarboxamidderivate und ihre verwendung als p38 kinase inhibitoren
ATE305787T1 (de)	2005-10-15	3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
ATE534649T1 (de)	2011-12-15	Imidazothiazole und imidazoxazolderivative als inhibitoren von p38
EA200601568A1 (ru)	2007-02-27	Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
NO20064415L (no)	2006-10-10	Nye amido-substituerte hydroksy-6-fenylfenantridiner og deres anvendelse som PDE4-inhibitorer
BRPI0409405A (pt)	2006-04-25	compostos 7-aza-quinazolina substituìdos
ATE336489T1 (de)	2006-09-15	Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren
DE602004007284D1 (de)	2007-08-09	Pyrimidine als inhibitoren von phosphoinositid-3-kinasen (pi3k)
EA200700098A1 (ru)	2007-06-29	Производные 4-арилморфолин-3-она, их получение и их применение в терапии
ATE215935T1 (de)	2002-04-15	Heterozyklische verbidungen mit mmp und tnf inhibitorisher wirkung